1. Home
  2. ITRG vs IVVD Comparison

ITRG vs IVVD Comparison

Compare ITRG & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Integra Resources Corp.

ITRG

Integra Resources Corp.

HOLD

Current Price

$2.71

Market Cap

543.8M

ML Signal

HOLD

Logo Invivyd Inc.

IVVD

Invivyd Inc.

HOLD

Current Price

$1.49

Market Cap

437.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ITRG
IVVD
Founded
1997
2020
Country
Canada
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
543.8M
437.1M
IPO Year
2017
2021

Fundamental Metrics

Financial Performance
Metric
ITRG
IVVD
Price
$2.71
$1.49
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
5
Target Price
$5.13
$8.75
AVG Volume (30 Days)
2.5M
2.6M
Earning Date
05-11-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
79.02
EPS
N/A
N/A
Revenue
N/A
$53,426,000.00
Revenue This Year
$67.34
$61.57
Revenue Next Year
$25.89
$41.42
P/E Ratio
$45.07
N/A
Revenue Growth
N/A
110.47
52 Week Low
$1.43
$0.49
52 Week High
$4.87
$3.07

Technical Indicators

Market Signals
Indicator
ITRG
IVVD
Relative Strength Index (RSI) 37.94 47.51
Support Level $2.57 $1.46
Resistance Level $3.29 $2.00
Average True Range (ATR) 0.13 0.10
MACD -0.02 -0.01
Stochastic Oscillator 13.71 32.69

Price Performance

Historical Comparison
ITRG
IVVD

About ITRG Integra Resources Corp.

Integra Resources Corp is a precious metals exploration and development company in the Great Basin of the Western USA. Integra is currently focused on advancing its two flagship oxide heap leach projects: the past-producing DeLamar Project located in southwestern Idaho and the Nevada North Project, comprised of the Wildcat and Mountain View deposits, located in northwestern Nevada. The company also holds a portfolio of prospective early-stage exploration projects in Idaho, Nevada, and Arizona.

About IVVD Invivyd Inc.

Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.

Share on Social Networks: